-
Mashup Score: 1FDA approves durvalumab for limited-stage small cell lung cancer - 2 month(s) ago
On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer (LS-SCLC).
Source: www.fda.govCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 61
Nature Reviews Clinical Oncology – The experience with PARP inhibitors provides evidence of the clinical utility of synthetic lethality, whereby the simultaneous presence of two specific…
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet-
In a Review now available online, Natalie Ngoi, David Gallo, Carlos Torrado, Mirella Nardo, Daniel Durocher & Tim Yap provide an updated and comprehensive overview of the role of systhetic lethal strategies in cancer therapy https://t.co/Yx76Qvts6F https://t.co/FHXtmjnIHe
-
-
Mashup Score: 58
Nature Reviews Clinical Oncology – The experience with PARP inhibitors provides evidence of the clinical utility of synthetic lethality, whereby the simultaneous presence of two specific…
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet-
In a Review now available online, Natalie Ngoi, David Gallo, Carlos Torrado, Mirella Nardo, Daniel Durocher & Tim Yap provide an updated and comprehensive overview of the role of systhetic lethal strategies in cancer therapy https://t.co/Yx76Qvts6F https://t.co/FHXtmjnIHe
-
-
Mashup Score: 2
Nature Reviews Clinical Oncology – Benefit with glofitamab plus chemotherapy in transplant-ineligible R/R DLBCL
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet-
In a Research Highlight now published online, we discussed the results of the phase III STARGLO trial testing addition of glofitamab to gemcitabine-oxaliplatin in transplant-ineligible diffuse large B cell #lymphoma https://t.co/xXshBP7KnE https://t.co/xYI9ju5pTd
-
-
Mashup Score: 3FDA approves updated drug labeling for fludarabine phosphate - 3 month(s) ago
On November 19, 2024, the FDA approved updated drug labeling for fludarabine phosphate (Fludarabine Phosphate Injection, Sandoz) under Project Renewal, an Oncology Center of Excellence (OCE) initiative aimed at updating labeling information for certain older oncology drugs.
Source: www.fda.govCategories: General Medicine News, Oncologists1Tweet-
The FDA had approved an updated drug labelling for fludarabine phosphate under 'Project Renewal', with revised dosage information for use in combination with cyclophosphamide and rituximab, and removal of a boxed warning: https://t.co/EusTCdbyqT
-
-
Mashup Score: 5FDA approves revumenib for relapsed or refractory acute leukemia - 3 month(s) ago
On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.
Source: www.fda.govCategories: General Medicine News, Oncologists1Tweet-
Last week, the FDA has approved revumenib, a menin inhibitor, for relapsed and/or refractory acute leukaemia with a KMT2A translocation, based on data from the single-arm AUGMENT-101 trial: https://t.co/tPMNh0V4EX
-
-
Mashup Score: 3On the cusp of targeted therapy for cancer cachexia — what clinical benefits might we promise our patients? - 3 month(s) ago
Nature Reviews Clinical Oncology – A number of therapeutics that target mediators of signalling in the hypothalamic and brainstem regions that control appetite, ingestive behaviour, satiety, nausea…
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet-
On the cusp of targeted therapy for cancer cachexia — what clinical benefits might we promise our patients? Herein, Vickie Baracos discusses recent developments in targeting GDF15 & the uncertainty surrounding the most relevant therapeutic effects: https://t.co/ki0US5xIuc https://t.co/UCHtrox3fc
-
-
Mashup Score: 11Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia - Nature Reviews Clinical Oncology - 3 month(s) ago
In several B cell malignancies, BTK is a crucial mediator of oncogenic signalling pathways and inhibitors of this kinase have substantially improved patient outcomes. This Review discusses the currently approved indications for covalent and non-covalent BTK inhibitors, as well as mechanisms of resistance, and novel BTK-targeted agents and treatment strategies that have the potential to further…
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet-
In a Review now online @MDStanch @Skyeintist @DanilovLab Jorge Castillo, Alvaro Alencar @JulioChavezMD @chanyooncheah Carlos Chiattone @YucaiWangMD @MCThompsonMD Paolo Ghia @TaylorJ_MD & @JuanAlderuccio summarize past knowledge & next steps with BTK inh: https://t.co/UUmbQVOMpm https://t.co/dLc1z4cSaf
-
-
Mashup Score: 520 years of Nature Reviews Clinical Oncology - 4 month(s) ago
In this Collection, we compile the most popular contents published over 20 years – including freely available recent articles
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet-
To celebrate the 20th anniversary of @NatRevClinOncol we have compiled some of the most popular contents we have published over the years in a collection - including some articles that will be freely available for a limited period of time: https://t.co/AtCZmZBhZz https://t.co/EI8Vux75IA
-
-
Mashup Score: 2The TOPGEAR trial — is chemoradiotherapy no longer a component of multidisciplinary care for gastric cancer? - 4 month(s) ago
Nature Reviews Clinical Oncology – Adjuvant chemoradiotherapy has a proven survival benefit for patients undergoing upfront resection of gastric cancer compared with surgery alone. Now, data from…
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet-
In a News & Views now published online, Brian Badgwell discuss the results of the TOPGEAR trial in the perioperative setting for gastric cancer https://t.co/HyWw5u44D1 https://t.co/27k4MSFUN3
-
The FDA has approved durvalumab as consolidation/maintenance therapy for patients with limited-stage small cell lung cancer that has not progressed following concurrent platinum-based chemoradiotherapy, based on OS & PFS improvements in the ADRIATIC trial: https://t.co/X84ukocpQj